$LJPC(LJPC)$网页链接 Oppenheimer started coverage on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) in a research note released on Monday morning,TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock.
Oppenheimer has also modified their ratings on a number of other stocks in the few days. The firm reiterated its outperform rating on shares of SAP SE. They have a $80.00 price target on that stock. Also, Oppenheimer raised its price target on shares of The Carlyle Group LP from $37.00 to $38.00. They have an outperform rating on that stock.
LJPC has been the subject of a number of other recent research reports. Analysts at Jefferies Group initiated coverage on shares of La Jolla Pharmaceutical Company in a research note on Tuesday, March 31st. They set a buy rating and a $25.00 price target on the stock. Analysts at HC Wainright raised their price target on shares of La Jolla Pharmaceutical Company from $20.00 to $29.00 and gave the company a buy rating in a research note on Friday, March 20th. Analysts at Noble Financial reiterated a positive rating on shares of La Jolla Pharmaceutical Company in a research note on Wednesday, March 18th. Finally, analysts at Chardan Capital set a $54.00 price target on shares of La Jolla Pharmaceutical Company and gave the company a buy rating in a research note on Tuesday, March 17th. Six analysts have rated the stock with a buy rating, The company has an average rating of Buy and an average price target of $36.50.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) traded up 6.72% on Monday, hitting $19.07. The stock had a trading volume of 95,578 shares. La Jolla Pharmaceutical Company has a one year low of $6.17 and a one year high of $24.89. The stock has a 50-day moving average of $20. and a 200-day moving average of $16.. The company’s market cap is $290.68 million.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.08. On average, analysts predict that La Jolla Pharmaceutical Company will post $-2.19 earnings per share for the current fiscal year.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics intended to significantly improve outcomes in patients with life-threatening diseases. The Company’s drug development efforts are focused on product candidates, including GCS-100, LJPC-501 and LJPC-401.